Secukinumab treatment of moderate to severe plaque
psoriasis in routine clinical care: real-life data of prior and
concomitant use of psoriasis treatments from the
* D. Thac
R. von Kiedrowski,
Department of Dermatology, University Hospital Essen, Essen, Germany
Comprehensive Center of Inﬂammation Medicine, University Medical Center Schleswig-Holstein, L
Dermatologische Spezialpraxis, Selters, Germany
Novartis Pharma GmbH, N
Hautzentrum Donau Alb, Blaubeuren, Germany
International Center for Skin Disease, DermAllegra, Hohenstadt/N
German Center for Health Services Research in Dermatology (CVderm), Institute for Health Services Research in Dermatology and
Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
*Correspondence: A. K
orber. E-mail: firstname.lastname@example.org
Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efﬁcacy and
safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psori-
asis treatments of a deﬁned minimal length were required and use of concomitant psoriasis medication was prohibited.
There is therefore a lack of data on the effect of shorter transition periods and concomitant psoriasis treatment with other
pharmacologically active substances on the effectiveness and safety of secukinumab in routine clinical practice.
Objectives The PROSPECT study was designed to assess prior and concomitant use of psoriasis treatments in sub-
jects receiving secukinumab and the duration of transition periods from prior treatments to secukinumab. Here, we
report the baseline characteristics and the duration of transition period in an interim analysis of the ﬁrst 805 subjects.
Methods PROSPECT is an ongoing 24-week, single-cohort, non-interventional study. Subjects with moderate to sev-
ere psoriasis with a decision to receive secukinumab were included.
Results The majority of subjects were male (491/796, 61.7%), with a mean age of 47.7 years (SD 13.7). The baseline
Psoriasis Area and Severity Index (PASI) was available for 92.4% (744/805) of subjects, and mean baseline PASI was
17.5 (SD 13.1); 93.4% (752/805) of subjects had signs of high disease severity. Use of concomitant treatment increased
with the number of signs. Within the last 12 months prior to inclusion, 10%, 40%, and 28% of subjects had received
topical, conventional systemic, or biologic treatments as their last prior psoriasis therapy, respectively, and 22% of sub-
jects had not received any psoriasis therapy. Discontinuation of prior treatment due to adverse events was high in sub-
jects with conventional systemic treatment (93/413, 22.5%) compared to biologic treatment (5/210, 2.4%). The median
duration of the transition period was 14.0, 30.5, and 38.0 days for prior topical, conventional systemic, and biologic
Conclusion PROSPECT is the ﬁrst study to investigate prior and concomitant use of psoriasis treatments in subjects
receiving secukinumab in a real-world setting. The majority of the subjects had a high disease burden and use of con-
comitant treatment increased with disease severity. The duration of the transition period depended on prior treatment.
Received: 30 July 2017; Accepted: 7 September 2017
Conﬂicts of interest
The study was funded by Novartis Pharma GmbH, Germany.
© 2017 European Academy of Dermatology and Venereology
2018, 32, 411–419